- Home
- STM vs ILMN Comparison
STM vs ILMN Comparison
Compare STM & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STM
- ILMN
- Stock Information
- Founded
- STM 1987
- ILMN 1998
- Country
- STM Switzerland
- ILMN United States
- Employees
- STM N/A
- ILMN N/A
- Industry
- STM Semiconductors
- ILMN Medical Specialities
- Sector
- STM Technology
- ILMN Health Care
- Exchange
- STM Nasdaq
- ILMN Nasdaq
- Market Cap
- STM 24.4B
- ILMN 23.6B
- IPO Year
- STM 1994
- ILMN 2000
- Fundamental
- Price
- STM $25.54
- ILMN $134.95
- Analyst Decision
- STM Buy
- ILMN Buy
- Analyst Count
- STM 8
- ILMN 17
- Target Price
- STM $37.63
- ILMN $163.12
- AVG Volume (30 Days)
- STM 5.5M
- ILMN 2.3M
- Earning Date
- STM 01-23-2025
- ILMN 02-06-2025
- Dividend Yield
- STM 1.40%
- ILMN N/A
- EPS Growth
- STM N/A
- ILMN N/A
- EPS
- STM 2.27
- ILMN N/A
- Revenue
- STM $14,229,000,000.00
- ILMN $4,390,000,000.00
- Revenue This Year
- STM N/A
- ILMN N/A
- Revenue Next Year
- STM $8.51
- ILMN $4.05
- P/E Ratio
- STM $10.90
- ILMN N/A
- Revenue Growth
- STM N/A
- ILMN N/A
- 52 Week Low
- STM $23.96
- ILMN $97.36
- 52 Week High
- STM $50.94
- ILMN $156.66
- Technical
- Relative Strength Index (RSI)
- STM 48.68
- ILMN 40.07
- Support Level
- STM $24.15
- ILMN $130.31
- Resistance Level
- STM $26.59
- ILMN $137.69
- Average True Range (ATR)
- STM 0.62
- ILMN 5.08
- MACD
- STM -0.03
- ILMN -1.03
- Stochastic Oscillator
- STM 52.41
- ILMN 21.62
About STM STMicroelectronics N.V.
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicroelectronics is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. It is an especially prominent chip supplier to the industrial and automotive industries.
About ILMN Illumina Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.